D&D Pharmatech’s MASH candidate gains credibility as Phase 2 findings enter peer review
Peer-reviewed Phase 2 data link zabopegdutide to rapid liver fat and stiffness reductions, while Phase 3 validation remains the decisive test.
Pharma & Biotech
Pharma & Biotech
OrsoBio’s TLC-2716 data point to a new oral route in severe metabolic lipid disease
Find out how OrsoBio’s TLC-2716 Phase 2a data could reshape severe hypertriglyceridemia and MASLD drug development.
Pharma & Biotech
insitro’s MASH candidate adds a fibrosis signal, but human proof remains the real test
AI met MASH fibrosis, but mouse data are only the first test. See why insitro’s CTRO-1013 signal matters now.
Pharma & Biotech
Novo Nordisk finalizes $5.2bn Akero deal to expand in advanced MASH care
Novo Nordisk has acquired Akero Therapeutics for up to $5.2 billion to advance efruxifermin, its Phase 3 MASH asset. Find out what this means for liver care.